Bristol-Myers Squibb announced Thursday that it’s going to acquire another drugmaker, Celgene. The deal is worth about $74 billion. The combined company will have nine products with sales of more than a billion dollars a year, including some blockbuster cancer drugs. The merger is a sign that Big Pharma is betting big on cancer medications.

Click the audio player above to hear the full story.